Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023

SEATTLE, WA. November 13, 2023 —Mozart Therapeutics, a leading developer of CD8 Treg Modulators for the treatment of autoimmune and inflammatory diseases, presented preclinical pharmacology and tolerability data for MTX-101, a CD8 Treg modulator at the annual meeting of the American College of Rheumatology being held at the San Diego Convention Center in San Diego, CA.

Presented findings demonstrate: 

• CD8 Treg are present in rheumatological autoimmune diseases and show decreased expression of functional proteins and reduced responsiveness to stimulation relative to healthy donor CD8 Treg
• MTX-101 selectively binds CD8 Treg and enhances their killing of self-reactive CD4 T cells by blocking inhibitory KIR
• Enhanced MTX-101 mediated CD8 Treg function prevents self-reactive CD4 T cell expansion and inflammation, without unwanted immune cell activation or increase of pro-inflammatory cytokines
• In non-clinical safety studies, MTX-101 was well-tolerated at doses up to 50 mg/kg 
• Data collectively support the therapeutic potential of MTX-101 for the treatment of autoimmunity including rheumatological diseases

“These results are important because they show the therapeutic potential of MTX-101 and validate the ability MTX-101 to restore the functionality of CD8 Treg in autoimmune diseases and to reestablish immune balance” said Kristine Swiderek, PhD, Chief Scientific Officer at Mozart Therapeutics.

The poster “Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases” (Abstract #0089) can be accessed from the Mozart Therapeutics website.  

About MTX-101

MTX-101 is a bispecific CD8 Treg Modulator targeting inhibitory KIR and CD8 expressed on regulatory CD8 T cells. This autoimmune checkpoint inhibitor aims to restore regulatory CD8 T cell function, acting early in the autoimmune disease process to halt downstream inflammation and prevent the perpetuation of tissue destruction. 

About Mozart Therapeutics

Mozart Therapeutics is focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, utilizing a novel approach to restoring immune system function by targeting the CD8 T regulatory network. The company is headquartered in Seattle, WA. For more information visit www.mozart-tx.com and follow the company on LinkedIn @Mozart-tx.

Media Contact: 
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219